Miacalcic

Calcitonin salmon, the active ingredient in Miacalcic, is a calcitonin (peptide hormone) presented as an injectable solution for intramuscular, intravenous, or subcutaneous use. It treats bone metabolism disorders such as postmenopausal osteoporosis, Paget's disease of bone, hypercalcemia of malignancy, acute bone pain, and osteogenesis imperfecta.

GNH USA supplies Miacalcic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Miacalcic is a calcitonin peptide used to manage disorders of bone turnover and calcium metabolism.

- Postmenopausal osteoporosis: reduces bone resorption and helps maintain bone density. - Paget's disease of bone: normalises abnormal bone remodeling and alleviates bone pain. - Hypercalcemia of malignancy: lowers elevated serum calcium levels. - Acute bone pain: provides rapid analgesic relief in metastatic bone disease. - Osteogenesis imperfecta: improves bone strength and reduces fracture risk.

Miacalcic may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Flushing: temporary redness of the face or neck. - Dizziness: light‑headed sensation, especially after injection. - Injection site reactions: pain, erythema, or swelling. - Headache: mild to moderate intensity. - Nasal irritation: when administered intranasally (if applicable).

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or angioedema. - Anaphylaxis: severe allergic response requiring immediate medical attention. - Severe hypocalcemia: markedly low calcium levels, potentially causing neuromuscular symptoms. - Acute renal impairment: rare cases of kidney function decline. - Cardiovascular events: rare instances of hypotension or arrhythmia.

Before initiating therapy with Miacalcic, consider the following safety measures.

- Assess calcium levels: monitor serum calcium before and during treatment. - Review medical history: evaluate for previous hypersensitivity to calcitonin. - Caution in renal impairment: adjust monitoring in patients with kidney disease. - Avoid concurrent calcitonin products: prevent duplication of therapy. - Pregnancy and lactation: use only if clearly needed, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Miacalcic can interact with other medications; awareness of these interactions helps optimise safety.

Major Interactions (Avoid): - Concurrent calcitonin preparations: risk of overdose and additive effects. - High‑dose calcium or vitamin D supplements: may diminish therapeutic efficacy.

Moderate Interactions (Monitor Closely): - Bisphosphonates: increased risk of hypocalcemia; monitor calcium levels. - Loop diuretics: may exacerbate electrolyte disturbances; check renal function. - NSAIDs: potential for gastrointestinal irritation; assess patient tolerance. - Anticoagulants: monitor for any changes in bleeding risk, although interaction is uncommon.